These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 7903392)

  • 21. Vasorelaxing effects of propranolol in rat aorta and mesenteric artery: a role for nitric oxide and calcium entry blockade.
    Priviero FB; Teixeira CE; Toque HA; Claudino MA; Webb RC; De Nucci G; Zanesco A; Antunes E
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):448-55. PubMed ID: 16700877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formation and role of plasma S-nitrosothiols in liver ischemia-reperfusion injury.
    Glantzounis GK; Rocks SA; Sheth H; Knight I; Salacinski HJ; Davidson BR; Winyard PG; Seifalian AM
    Free Radic Biol Med; 2007 Mar; 42(6):882-92. PubMed ID: 17320770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A redox-based mechanism for nitric oxide-induced inhibition of DNA synthesis in human vascular smooth muscle cells.
    Bundy RE; Marczin N; Chester AH; Yacoub M
    Br J Pharmacol; 2000 Apr; 129(7):1513-21. PubMed ID: 10742309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding the controversy over the identity of EDRF.
    Feelisch M; te Poel M; Zamora R; Deussen A; Moncada S
    Nature; 1994 Mar; 368(6466):62-5. PubMed ID: 8107883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic characteristics of non-prostanoid, non-nitric oxide mediated and endothelium-dependent relaxation of guinea-pig aorta in response to substance P.
    Tanaka Y; Kaneko H; Tanaka H; Shigenobu K
    Res Commun Mol Pathol Pharmacol; 1999 Jan; 103(1):65-81. PubMed ID: 10440572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New chemical and biological aspects of S-nitrosothiols.
    Wang K; Zhang W; Xian M; Hou YC; Chen XC; Cheng JP; Wang PG
    Curr Med Chem; 2000 Aug; 7(8):821-34. PubMed ID: 10828289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vasodilator-derived nitric oxide inhibits fetal calf serum- and angiotensin-II-induced growth of renal arteriolar smooth muscle cells.
    Dubey RK
    J Pharmacol Exp Ther; 1994 Apr; 269(1):402-8. PubMed ID: 8169847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the action of nitric oxide prodrugs by pyocyanin: mechanistic studies.
    Hussain AS; Bozinovski J; Maurice DH; McLaughlin BE; Marks GS; Brien JF; Nakatsu K
    Can J Physiol Pharmacol; 1997 May; 75(5):398-406. PubMed ID: 9250373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. S-Nitrosothiols as potential therapeutics to induce a mobilizable vascular store of nitric oxide to counteract endothelial dysfunction.
    Perrin-Sarrado C; Zhou Y; Salgues V; Parent M; Giummelly P; Lartaud I; Gaucher C
    Biochem Pharmacol; 2020 Mar; 173():113686. PubMed ID: 31678494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential therapeutic uses for S-nitrosothiols.
    Richardson G; Benjamin N
    Clin Sci (Lond); 2002 Jan; 102(1):99-105. PubMed ID: 11749666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. S-Nitrosothiols: a class of nitric oxide-donor drugs.
    Al-Sa'doni H; Ferro A
    Clin Sci (Lond); 2000 May; 98(5):507-20. PubMed ID: 10781381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of activation of soluble guanylate cyclase by guanidine thiols--a new class of enzyme activators.
    Severina IS; Bussygina OG; Vinograd LH; Grigoryev NB
    Biochem Mol Biol Int; 1996 Mar; 38(3):509-18. PubMed ID: 8829610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel S-nitrosothiol (RIG200) causes prolonged relaxation in dorsal hand veins with damaged endothelium.
    Sogo N; Wilkinson IB; MacCallum H; Khan SQ; Strachan FE; Newby DE; Megson IL; Webb DJ
    Clin Pharmacol Ther; 2000 Jul; 68(1):75-81. PubMed ID: 10945318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates.
    Ignarro LJ; Lippton H; Edwards JC; Baricos WH; Hyman AL; Kadowitz PJ; Gruetter CA
    J Pharmacol Exp Ther; 1981 Sep; 218(3):739-49. PubMed ID: 6115052
    [No Abstract]   [Full Text] [Related]  

  • 35. Interaction between stimulators of adenylate and guanylate cyclases in human leukocytes, platelets and arteries.
    Gryglewski RJ; Korbut R; Kalecinska A; Zembowicz A
    Int J Tissue React; 1989; 11(6):269-75. PubMed ID: 2483990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide.
    Jurasz P; Sawicki G; Duszyk M; Sawicka J; Miranda C; Mayers I; Radomski MW
    Cancer Res; 2001 Jan; 61(1):376-82. PubMed ID: 11196190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
    Nielsen-Kudsk JE
    Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained nitric oxide exposure decreases soluble guanylate cyclase mRNA and enzyme activity in pulmonary artery smooth muscle.
    Scott WS; Nakayama DK
    J Surg Res; 1998 Sep; 79(1):66-70. PubMed ID: 9735242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel family of S-nitrosothiols: chemical synthesis and biological actions.
    Al-Sa'doni HH; Khan IY; Poston L; Fisher I; Ferro A
    Nitric Oxide; 2000 Dec; 4(6):550-60. PubMed ID: 11139363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new class of furoxan derivatives as NO donors: mechanism of action and biological activity.
    Ferioli R; Folco GC; Ferretti C; Gasco AM; Medana C; Fruttero R; Civelli M; Gasco A
    Br J Pharmacol; 1995 Feb; 114(4):816-20. PubMed ID: 7773542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.